IRCT20151227025726N9 IRCT 2018-08-15 Shahid Beheshti University of Medical Sciences The Role of Aerosolized Colistin in the Treatment of Ventilator-associated Pneumonia, Caused by Multidrug-resistant Gram-negative Bacteria Evaluation of Aerosolized (AS) Colistin as Adjunctive Treatment Versus Intravenous Colistin Alone in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by Multidrug-resistant Gram-negative Bacteria 2016-04-04 anticipated 34 Complete https://irct.ir/trial/21471 interventional Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: Investigator, outcome assessors, and data analyser were blind to the study groups untill the end of the study. 3 Ventilator-associated Pneumonia (VAP). Intervention 1: Intervention group: Received IV colistin (Colistimethate Sodium Injection, powder for solution parenteral 1000000 [IU] that belongs to Forest Laboratories Uk) based on Glomerular Filtration Rate (GFR) plus two million units of AS colistin , three times per day. Dose adjustments of IV Colistin were implemented based on table that belongs to Systematic review of the evidence for rational dosing of colistin. Prescribtion of IV colistin was countinued until the infection was completely resolved; AS colistin was prescribed only for a period of seven days (OMRON Mesh Nebulizer Model NE-U22). To prevent bronchospasm caused by nebulized colistin, patients were premedicated with salbutamol prior to administration of nebulized colistin. Intervention 2: Control group: Intravenous Colistin based on Glomerular Filtration Rate. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.